Advertisement
Screener

WINDTREE THERAPEUTICS INC /DE/ (WINT) Revenue from Contract with Customer, Including Assessed Tax

WINDTREE THERAPEUTICS INC /DE/ Revenue from Contract with Customer, Including Assessed Tax

WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Revenue from Contract with Customer, Including Assessed Tax of $198.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-29.

Discontinued › Income Statement › Revenue

us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2021-03-29

  • WINDTREE THERAPEUTICS INC /DE/ revenue from contract with customer, including assessed tax for the quarter ending 2019-12-31 was $0.00.
  • WINDTREE THERAPEUTICS INC /DE/ revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $0.00.
  • WINDTREE THERAPEUTICS INC /DE/ revenue from contract with customer, including assessed tax for the quarter ending 2019-06-30 was $158.00K.
  • WINDTREE THERAPEUTICS INC /DE/ revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $40.00K.
  • WINDTREE THERAPEUTICS INC /DE/ revenue from contract with customer, including assessed tax for fiscal 2019 was $198.00K.
Period endRevenue from Contract with Customer, Including Assessed Tax 3 monthRevenue from Contract with Customer, Including Assessed Tax 6 monthRevenue from Contract with Customer, Including Assessed Tax 9 monthRevenue from Contract with Customer, Including Assessed Tax 12 month
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$0.00
derived: sum of 2 quarters · filed 2021-03-29
$158.00K
derived: sum of 3 quarters · filed 2021-03-29
$198.00K
10-K · filed 2021-03-29
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16
$158.00K
derived: sum of 2 quarters · filed 2020-11-16
$198.00K
10-Q · filed 2020-11-16
2019-06-30$158.00K
10-Q · filed 2020-08-14
$198.00K
10-Q · filed 2020-08-14
2019-03-31$40.00K
10-Q · filed 2020-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
CURIS INC (CRIS)United States$0.002B-0.05
Silexion Therapeutics Corp (SLXN)$0.001B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70